Two major eye drop recalls in early 2026 have exposed millions of American consumers to potential eye infection risks — and a wave of class action lawsuits is already underway. The eye drop recall lawsuit 2026 landscape involves overlapping crises at K.C. Pharmaceuticals and Alcon Research LLC, affecting products sold at CVS, Walgreens, Kroger, Publix, and dozens of other national retailers. If you used recalled eye drops this year, here is everything you need to know about the recalls, the litigation, and your legal options.
Two Separate Recalls, One Alarming Pattern: What Happened in Early 2026
The first major recall of 2026 came on March 3, when K.C. Pharmaceuticals of Pomona, California, voluntarily recalled 3,111,072 bottles of over-the-counter eye drops due to a lack of assurance of sterility. The FDA classified this as a Class II recall, meaning the products may cause temporary or medically reversible adverse health consequences. Eight distinct product lines were pulled from shelves, including Dry Eye Relief, Artificial Tears Sterile Lubricant, Sterile Eye Drops Original Formula, Sterile Eye Drops Redness Lubricant, Eye Drops Advanced Relief, Ultra Lubricating Eye Drops, Sterile Eye Drops AC, and Sterile Eye Drops Soothing Tears.
Then, in April 2026, Alcon Research LLC separately recalled all unexpired lots of its Systane Night Gel Comforting Dry Eye Relief and GenTeal Tears Lubricant Eye Gel products — also citing lack of assurance of sterility. The contamination source was traced to Excelvision Fareva, a contract manufacturing facility in France. Additional brands manufactured at the same facility — including Harrow Eye LLC’s Freshkote PF, OASIS Medical’s Oasis Tears PF, Scope Health’s Optase Dry Eye Intense, and Thea Pharma’s Ivizia Lubricant Eye Drops — were also implicated. The eye drop recall lawsuit 2026 filings that followed allege these were not isolated manufacturing failures but the predictable result of years of ignored warning signs.
The FDA’s Documented Warning History: Repeated Red Flags Before the Recalls
What makes both recalls especially troubling for mass tort attorneys and consumer advocates is the documented pattern of prior FDA intervention at both manufacturers. K.C. Pharmaceuticals had already been flagged by the FDA following a 2023 inspection, which resulted in a warning letter directing the company to change sterility protocols and consult outside experts. The 2026 recall strongly suggests those quality control improvements were never fully implemented — making this the second time since 2023 that federal regulators identified sterility concerns at the same Pomona facility.
The regulatory history at Excelvision Fareva is even more extensive. Mold contamination on aseptic filling lines at the French facility dates back to 2022, with documented presence of Penicillium citrinum, Fusarium oxysporum, and Aspergillus species. The FDA issued a formal Warning Letter to Excelvision in May 2025 following inspections in November 2024 and July 2023, identifying violations in sterility and aseptic processing. When the FDA re-inspected Excelvision in January 2026, it found 11 new citations, six of which were directly related to aseptic processing and microbiological contamination. In late April 2026, the FDA placed Excelvision on an Import Alert, effectively barring all its products from the U.S. commercial market. Critically, Alcon had confirmed as recently as October 2025 that it had not changed manufacturing facilities away from Excelvision, even after receiving the May 2025 FDA Warning Letter.
Why Non-Sterile Eye Drops Are Dangerous: The Medical Reality
The human eye is uniquely vulnerable to infection. Because the immune system has limited access to the interior of the eyeball, bacterial and fungal infections that enter through contaminated eye drops can escalate quickly and cause severe, lasting damage. The FDA requires all ophthalmic drugs to be sterile precisely for this reason. Cleveland Clinic ophthalmologist Dr. Nicole Bajic has noted that non-sterile eye drops create a direct pathway for pathogens to bypass the body’s normal immune defenses. Consumers who used recalled products labeled as sterile or preservative-free had no reason to believe they were introducing potential contaminants directly onto the surface of their eyes — which is at the heart of every eye drop recall lawsuit 2026 currently filed. Anyone who suffered an eye infection after using these products may have a personal injury claim; use a personal injury settlement calculator to get a preliminary estimate of potential damages.
Eye Drop Recall Data at a Glance: 2026 Key Statistics
| Recall Detail | K.C. Pharmaceuticals | Alcon / Excelvision |
|---|---|---|
| Recall Date | March 3, 2026 | April 2026 |
| Units / Lots Recalled | 3,111,072 bottles | All unexpired lots |
| FDA Recall Classification | Class II | Class II |
| Reason for Recall | Lack of assurance of sterility | Lack of assurance of sterility |
| Retailers Affected | CVS, Walgreens, Rite Aid, Kroger, Publix, Dollar General, Harris Teeter, Circle K | National retailers (name-brand channels) |
| Prior FDA Warnings | Warning letter after 2023 inspection | Warning letters 2023, 2025; 11 new citations January 2026 |
| Mold Species Identified | Not publicly specified | Penicillium citrinum, Fusarium oxysporum, Aspergillus |
| Import Alert Issued | N/A | Late April 2026 (Excelvision) |
| Class Actions Filed (as of June 2026) | Pending | At least 3 separate federal/state actions |
| Confirmed Injuries (as of filing date) | None confirmed | None confirmed |
The Class Action Lawsuits Filed Against Alcon in 2026
The litigation component of the eye drop recall lawsuit 2026 story moved quickly after the Alcon recall. On May 14, 2026, a federal class action lawsuit captioned Bibi Khan v. Alcon Laboratories was filed in federal court, alleging that Alcon marketed Systane Night Gel and GenTeal Tears as sterile products while knowing of contamination risks at the Excelvision facility. A second lawsuit — Som-Dotson v. Alcon Laboratories, Case No. 2:26-cv-04898, filed in Los Angeles Superior Court — alleged that the products were falsely advertised as preservative-free. A third class action, reported by ClassAction.org in May and June 2026, seeks a nationwide class of all U.S. purchasers of both recalled Alcon products within the applicable statute of limitations period.
The legal theories advanced across these cases are substantial and varied. Plaintiffs assert claims for deceptive business practices, negligence, unjust enrichment, breach of express and implied warranty, and violations of New York General Business Law. Remedies sought include compensatory damages covering the purchase price of recalled products, punitive damages, an injunction barring the use of “sterile” labeling for products with unverified sterility, and attorneys’ fees. For consumers who suffered serious eye infections requiring medical treatment, the damages picture expands significantly — and those victims may benefit from consulting a medical malpractice calculator to evaluate the full scope of their economic and non-economic losses from a defective pharmaceutical product.
Who Is Affected: Retailers, Products, and Consumer Exposure
The breadth of consumer exposure in both recalls is staggering. K.C. Pharmaceuticals products were sold as store-brand eye drops at some of the most-trafficked retail chains in the country, including CVS, Walgreens, Rite Aid, Kroger, Publix, Harris Teeter, Dollar General, and Circle K. Because these products were marketed under retailer house brands, many consumers had no idea their affordable store-brand eye drops were manufactured by K.C. Pharmaceuticals or that they bore the same sterility concerns at issue in the eye drop recall lawsuit 2026 proceedings.
The Alcon recall adds name-brand product consumers to the affected pool. Systane and GenTeal are widely trusted, premium-priced brands commonly recommended by eye care professionals. Consumers who paid a premium specifically because these products were marketed as sterile and preservative-free have a particularly strong basis for economic-loss claims — even if they did not suffer a physical injury. Under class action law principles, purchasers who paid for a product that did not deliver its promised quality (sterility) may recover the purchase price or price premium without needing to demonstrate personal physical injury.
Action Guide: What to Do If You Used a Recalled Eye Drop Product
If you purchased or used any of the recalled products in 2026, take the following steps immediately to protect both your health and your legal rights:
- Stop using the product immediately. Do not use any K.C. Pharmaceuticals eye drops purchased at CVS, Walgreens, Rite Aid, Kroger, Publix, Harris Teeter, Dollar General, or Circle K, or any Systane Night Gel or GenTeal Tears products from unexpired lots. Also check for Freshkote PF, Oasis Tears PF, Optase Dry Eye Intense, and Ivizia Lubricant Eye Drops from the Excelvision manufacturing chain.
- Seek medical attention for any symptoms. Eye redness, discharge, increased pain, sensitivity to light, or blurred vision that developed after using a recalled product should be evaluated by an ophthalmologist immediately. Document your visit and keep all medical records and receipts.
- Preserve the product and its packaging. Do not discard the recalled eye drop bottle or box. The lot number, expiration date, and UPC code are critical evidence for any legal claim.
- Document your purchase history. Locate receipts, credit card statements, loyalty program records, or any other proof of purchase. Retailers like CVS and Walgreens maintain digital purchase histories through their rewards programs.
- Report to the FDA. File a voluntary MedWatch safety report at FDA MedWatch to document your experience and contribute to the federal safety record.
- Consult a mass tort attorney. Both personal injury claims (for those who developed infections) and economic-loss class action claims (for all purchasers) may be viable. Time limits under state statutes of limitations apply, so acting promptly is essential.
Frequently Asked Questions About the Eye Drop Recall Lawsuit 2026
What products are included in the 2026 eye drop recalls?
The K.C. Pharmaceuticals recall announced March 3, 2026 covers 3,111,072 bottles across eight product lines: Dry Eye Relief, Artificial Tears Sterile Lubricant, Sterile Eye Drops Original Formula, Sterile Eye Drops Redness Lubricant, Eye Drops Advanced Relief, Ultra Lubricating Eye Drops, Sterile Eye Drops AC, and Sterile Eye Drops Soothing Tears — sold as store brands at CVS, Walgreens, Rite Aid, Kroger, Publix, and other major retailers. The Alcon recall in April 2026 covers all unexpired lots of Systane Night Gel Comforting Dry Eye Relief and GenTeal Tears Lubricant Eye Gel, along with products from other brands manufactured at the Excelvision Fareva facility in France, including Freshkote PF, Oasis Tears PF, Optase Dry Eye Intense, and Ivizia Lubricant Eye Drops.
Do I need to have a confirmed eye infection to join an eye drop recall lawsuit in 2026?
No. There are two distinct types of claims in the eye drop recall lawsuit 2026 litigation. Personal injury claims require documented physical harm — such as a bacterial or fungal eye infection — caused by using a recalled product. However, economic-loss class action claims allow any consumer who purchased a recalled product to seek reimbursement of the purchase price or price premium paid for a product that was marketed as sterile but could not be verified as such. At least three separate class actions against Alcon seek nationwide classes of all U.S. purchasers, regardless of whether they suffered physical harm.
Why were Alcon’s Systane Night Gel and GenTeal Tears recalled in 2026?
Alcon recalled all unexpired lots of both products in April 2026 due to a lack of assurance of sterility traced to the Excelvision Fareva contract manufacturing facility in France. The FDA re-inspected Excelvision in January 2026 and found 11 new citations, six related to aseptic processing and microbiological contamination. The facility had a mold contamination history dating to 2022, involving species including Penicillium citrinum, Fusarium oxysporum, and Aspergillus. The FDA issued an Import Alert against Excelvision in late April 2026, barring its products from the U.S. market. Class action lawsuits allege Alcon knew of these contamination risks but continued marketing its products as sterile and preservative-free.
What lawsuits have been filed over the Alcon eye drop recall in 2026?
As of June 2026, at least three class action lawsuits have been filed. The first, Bibi Khan v. Alcon Laboratories, was filed May 14, 2026 in federal court, alleging deceptive sterile labeling. The second, Som-Dotson v. Alcon Laboratories (Case No. 2:26-cv-04898), was filed in Los Angeles Superior Court alleging false preservative-free advertising. A third nationwide class action seeks to represent all U.S. purchasers of both recalled Alcon products within the statute of limitations. Legal theories include negligence, deceptive business practices, unjust enrichment, breach of express and implied warranty, and violations of New York General Business Law. Remedies sought include compensatory damages, punitive damages, and an injunction against sterile labeling for unverified products.
How long do I have to file an eye drop recall lawsuit claim in 2026?
The deadline to file a claim depends on your state’s statute of limitations and the type of claim you are bringing. For personal injury claims arising from an eye infection, most states impose a statute of limitations of one to three years from the date of injury or discovery of injury. For economic-loss class action claims, the limitations period varies by state and legal theory. Because the recalls occurred in March and April 2026 and class actions were filed as early as May 2026, time is a significant factor. Anyone who purchased or was injured by a recalled product should consult a qualified mass tort attorney as soon as possible to preserve their rights before any applicable deadline expires.
This article is provided for informational purposes only and does not constitute legal advice, nor does it create an attorney-client relationship.
Related reading: Personal Injury Settlement Guide 2026-07-11
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.